NCT03707899View on ClinicalTrials.gov

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

February 18, 2019

Study Completion Date

May 22, 2019

Conditions
Hypertension With Dyslipidemia
Interventions
DRUG

JLP-1401

Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

DRUG

Telmisartan/Amlodipine, Rosuvastatin

Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

NCT03707899 - The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers | Biotech Hunter | Biotech Hunter